Caxton Associates (New York)’s iShares Biotechnology ETF IBB Stock Holding History

Caxton Associates (New York)’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,156,519	Closed	-$152M	–	558
2022 Q4	$152M	Buy	+1,156,519	New	+$149M	10.13%	2

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Caxton Associates (New York)'s IBB Position: Q1 2023 in Review

Caxton Associates (New York) sold out of iShares Biotechnology ETF (IBB) in Q1 2023, closing a stake of 1,156,519 shares — an estimated $152M sold.

Caxton Associates (New York) first reported a position in IBB in Q4 2022 and held it in 1 quarter. The position peaked at $152M in Q4 2022. 866 funds tracked by Wall St. Rank hold IBB as of Q1 2023.

Caxton Associates (New York) reported no remaining iShares Biotechnology ETF position as of Q1 2023 after selling out during the quarter.
Caxton Associates (New York) sold 1,156,519 iShares Biotechnology ETF shares in Q1 2023, an estimated $152M.
Caxton Associates (New York) first reported a position in iShares Biotechnology ETF in Q4 2022 and held it in 1 quarter.
Caxton Associates (New York)'s iShares Biotechnology ETF position peaked at $152M in Q4 2022.
866 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.